Skip to main content

Role of glutamine and its metabolite ammonia in crosstalk of cancer-associated fibroblasts and cancer cells

Abstract

Cancer-associated fibroblasts (CAFs), the most abundant cells in the tumor microenvironment, play an indispensable role in cancer initiation, progression, metastasis, and metabolism. The limitations of traditional treatments can be partly attributed to the lack of understanding of the role of the tumor stroma. For this reason, CAF targeting is gradually gaining attention, and many studies are trying to overcome the limitations of tumor treatment with CAF as a breakthrough. Glutamine (GLN) has been called a “nitrogen reservoir” for cancer cells because of its role in supporting anabolic processes such as fuel proliferation and nucleotide synthesis, but ammonia is a byproduct of the metabolism of GLN and other nitrogenous compounds. Moreover, in some studies, GLN has been reported as a fundamental nitrogen source that can support tumor biomass. In this review, we discuss the latest findings on the role of GLN and ammonia in the crosstalk between CAFs and cancer cells as well as the potential therapeutic implications of nitrogen metabolism.

Introduction

Glutamine (GLN) is a non-essential amino acid that can be synthesized by cells via GLN synthetase (GS). It is abundant in the blood in the form of free amino acids. Cancer cells absorb and utilize GLN at high rates [1, 2]. Previous studies have shown that GLN mainly functions as a supplement to TCA cycle and nucleotide biosynthesis [3, 4]. However, GLN plays an important role in all aspects of carcinogenesis, such as antioxidant defense, chromatin modification/gene transcription, bioenergy, transportation of other amino acids across the plasma membrane, and the regulation of cell signaling [5]. GLN metabolism-related inhibitors have been approved by the FDA for the treatment of cancer and other diseases, and many of these inhibitors are currently being investigated in clinical trials [6].

When GLN is broken down to glutamate, ammonia is formed as a byproduct and is generally considered a toxic metabolite. However, recent studies on the role of ammonia in tumors have started reporting diverging data; one hypothesis is that ammonia is a metabolic waste product that inhibit tumor growth, whereas the other is that an appropriate amount of ammonia can promote tumor growth and support biomass production [7, 8].

The tumor microenvironment (TME) plays an important role in the utilization of GLN and ammonia, synthesis and secretion of GLN, sensing of changes in the concentration of GLN and ammonia, secretion of cytokines that affect GLN metabolism in cancer cells, and alterations in tumor cell proliferation and metastasis [9]. The TME is a complex combination of both pro-tumorigenic and anti-tumorigenic components, including varieties of immune cells, endothelial cells, mesenchymal stem cells, and fibroblasts (both CAFs and normal fibroblasts), as well as the extracellular matrix (ECM). The imbalance between ECM synthesis and turnover results in vascular dysplasia, disordered collagen formation, and abnormal secretion of cytokines [10,11,12,13]. Data on these elements pave the way for further research on the crosstalk between cancer cells and cells located in the stroma. CAFs are the main producers of ECM and paracrine signals that promote the formation of stem cell niches, tumor growth, immunosuppression, metastasis, and chemoresistance (Fig. 1) [14].

Fig. 1
figure1

Origins and functions of CAFs. The main origin of CAFs include epithelial cells, mesenchymal stem cells, mesothelial cells, normal fibroblasts, cancer cells, adipocytes and so on. The influence of CAFs on tumor cells includes various aspects like drug resistance, tumor proliferation, metastasis, invasion, migration, immunomodulation, and angiogenesis

GLN level in the ECM is regulated by both CAFs and other cancer cells [15]. The concentration and metabolites of GLN, particularly ammonia, act as signals that mediate the metabolic processes of cancer cells and CAFs [16]. GLN plays a vital role in tumor development because most tumor cells require GLN for growth. However, in the traditional sense, ammonia, a metabolic waste product, has also been reported to be conducive to tumor cell activity [7]. This new finding was possibly because the recent research on tumors is not limited to cancer cells alone but instead focuses on the complex and diverse TME [17]. Therefore, while reviewing the metabolism of GLN and ammonia, this article will focus on the metabolic processes in which fibroblasts participate, providing insights into the development of new treatment modalities for tumors.

Role of GLN in cancer cells

Although most cancer metabolic pathways are associated with aerobic glycolysis [18], GLN, as a non-essential amino acid, also has a cancer-promoting effect in many tumors [19]. In some cancers, such as pancreatic and breast cancers, GLN is one of the most rapidly utilized nutrients after glucose [20, 21]. Davidson et al. reported that both lung cancer cells and normal lung cells utilize minute quantities of exogenous GLN [22]. Different levels of GLN are utilized in different cancers [22,23,24]. In hyperglutamine-dependent cancer cells, GLN is used to synthesize amino acids, proteins, lipids, and nucleotides and regulate cancer cell metabolism [25]. Here, we discuss the role of GLN in cancer cells as well as the mechanism underlying its metabolic regulation.

GLN transport

Usually, GLN is transported into cancer cells mostly by alanine-serine-cysteine-transporter-2 (also called SLC1A5) followed by SLC6A14 and SLC38A5 [26]. According to the Cancer Cell Line Encyclopedia project and other studies, SLC1A5 is overexpressed in many solid cancers, such as colon, gastric, lung, and prostate cancers [27]. SLC1A5 is mainly involved in GLN import into cells, leading to cancer cell proliferation [28]. c-MYC, RNF5, and microRNA-137 have been confirmed to regulate SLC1A5 expression, but other mechanisms regulating SLC1A5 still need to be investigated [29,30,31]. GLN transported into cells via SLC1A5 can be directly used in cell metabolism or can be exchanged for leucine, valine, and other essential amino acids via the L-type amino acid transporter (also called SLC7A5) for indirect utilization in cells [32]. SLC7A5 is an external transporter of GLN that regulates the balance of the GLN flux [33]. GLN, when used in cell metabolism, can be catalyzed to glutamate via mitochondrial glutaminase (GLS), cytosolic enzymes, and other glutamate-producing enzymes. Glutamate may also be transported out of the cell by the SLC7A11 antiporter in exchange for cysteine [34]. SLC7A11 mainly regulates the redox status, ferroptosis, and intercellular signaling, leading to an increase in resistance to treatments such as chemotherapy and radiotherapy [35]. SLC7A11 expression is promoted by many oncogenes, such as KRAS and PTEN [36, 37]. Tumor suppressors, such as P53 activating transcription factor 3 and signal transducer and activator of transcription 3, inhibit SLC7A11 expression and transcription (Fig. 2) [38,39,40].

Fig. 2
figure2

Glutamine metabolism between CAFs and cancer cells. CAFs can provide cancer cells with Lac, Gln and other nutrients into TCA cycle and urea cycle, and then promote the growth and development of tumor cells.The black pointed arrow heads indicate material transportation. The blue blunt arrowheads indicate inhibitory interactions. Arg ariginine, α-KG α-Ketoglutaric acid, Cit citrate, Lac lactose, Glc glucose, Glu glutamate, GSH glutathione, Orn ornithine, PYR pyruvate

Oncogenic regulation of GLN metabolism

Advances in research and deeper understanding of tumor have shown that the metabolism of tumor cells is regulated by various genes. Recent studies have found that Myc, mTOR, p53, and mitogen-activated protein kinase (MAPK) are the major oncogenes associated with GLN metabolism [41].

MYC is a proto-oncoprotein that regulates the uptake, utilization, and decomposition of GLN [42]. In some types of human and mouse cancers, MYC induces the overexpression of glutamate ammonia ligase (GLUL), also called GS, which is responsible for de novo GLN synthesis. Cell and animal experiments in mammary epithelial cancer, pancreatic ductal neoplasia, T-cell lymphoma, and lung cancer cells have reported that MYC promotes GS expression to increase cell proliferation capacity [43, 44]. MYC overexpression is beneficial for GLN utilization as it transforms the substrate of the tricarboxylic acid cycle from glucose to GLN [41]. However, it promotes the utilization of GLN as an amino acid substrate by stimulating the synthesis of asparagine and other amino acids [45]. In addition, MYC promotes GLN uptake by transactivating the GLN transporters SLC1A5 and SLC7A5/SLC3A2. Moreover, it suppresses the transcription of GLS repressor microRNAs-23a/b to increase the expression of GLS, thereby promoting GLN utilization [42, 46, 47]. Furthermore, three other key enzymes involved in GLN utilization are phosphoribosylpyrophosphate (PRPP) amidotransferase, carbamoyl phosphate synthetase II, and CTP synthetase, which are all directly modulated by MYC at the transcriptional level [48]. Interestingly, Wise et al. found that although PI3K/AKT and MYC both regulate the uptake of GLN, the former is not a necessary factor in the process of MYC-mediated GLN uptake [45].

The mammalian target of rapamycin (mTOR) signaling pathway senses changes in the extracellular environment and regulates the collective homeostasis response [49]. It has been previously found that GLN stimulates mTOR signaling. The amino acid pool maintained by GLN in cancer cells is an important factor in the stimulation of mTOR signaling [50]. GLN is the rate-limiting factor in mTOR activation [51]. Cancer cells absorb GLN through SLC1A5 and efflux it through SLC7A5 in exchange for leucine and other essential amino acids (EAAs). The exchanged leucine stimulates mTOR complex 1 (mTORC1) through the Ras-related GTPase (RAG) complex [52]. GLN promotes its own decomposition by binding with leucine, thus activating mTORC, affecting cell growth and autophagy [53]. mTORC1 downregulates SIRT4 by reducing the stability of the proteasome-mediated cAMP response element binding 2 and increasing the expression of glutamate dehydrogenase (GDH), thus resulting in GLN supplementation [54,55,56]. In addition, SLC1A5 silencing in hepatocellular carcinoma can prevent tumor growth and expansion by inhibiting mTOR signal transmission during the translation process [57].

The acidic TME leads to p53-mediated metabolic reprogramming, which enhances GLN metabolism [51]. GLS2 (liver-type glutaminase) has a different role in distinct cancers. GLS2 regulation by p53 has been confirmed in both non-tumor and tumor cells [58, 59]. The GLS2 gene contains a p53 consensus DNA-binding element that promotes interaction between the GLS2 promoter and the p53 gene [55]. Subsequently, P53 promotes GLS2 expression, both in stress and non-stress conditions, to break down GLN and produce more glutathione and NADH. This results in lowering of intracellular reactive oxygen species (ROS) levels in cells, ultimately targeting energy metabolism and apoptosis [60,61,62].

The MAPK pathway is another major player in cancer. Yuan et al. revealed that GLN regulates the mTOR/S6 and MAPK pathways to increase the activities of both GLS and GDH [63]. GLN activates the MAPK pathway to promote proliferation, metastasis, and differentiation of human dental pulp cells [64]. Contrastingly, in macrophages, the MEK/ERK pathway is not a regulator of GLN metabolism [65, 66]. MAPK plays different roles in GLN metabolism in various cell types, which may be because of the unique responses of different types of cells at various nutrition levels [64, 67]. Tumor cells have more potential to proliferate when they are rich in nutrients, whereas immune cells do not show major changes; this is because of the differing metabolic characteristics of the cell types [68]. Therefore, in GLN research, we should consider the functional differences among cell types under physiological conditions, before studying the metabolism differences for GLN (Fig. 3).

Fig. 3
figure3

Oncogenic regulation of GLN metabolism. Driven by oncogenes and ammonia concentration, CAFs can secrete nutrients such as Glu and cytokines, thus promoting the metabolic changes of tumor cells and the growth and development of cancer cells. The red pointed arrow heads indicate activation interactions. The black pointed arrow heads indicate material transportation. The blue blunt arrowheads indicate inhibitory interactions

Role of ammonia in cancer

Ammonia is another metabolite that is produced when GLN is decomposed by GS. In earlier studies, ammonia was found to be a toxic metabolic waste product of nitrogenous compounds, such as GLN [69,70,71]. However, ammonia is usually metabolized into urea through the Krebs cycle and excreted from the body. High concentrations of ammonia may cause autophagy in cancer cells [16].

However, Spinelli et al. reported that growth inhibition of breast cancer cells owing to a GLS inhibitor ceased when ammonia was artificially added [7]. As previously reported, ammonia supports human liver cancer cell growth in GLN-free media [72]. Physiological concentrations of ammonia in the plasma of healthy human adults range from 0 to 50 μM. However, it can be present at up to 150 μM in patients with hyperammonemia [71]. When researchers altered ammonia concentrations in breast cancer cells from 0 to 1 mM, the uptake of GLN or glucose and the expression of GS, GDH, and carbamoyl phosphate synthetase I (CPS1) ammonia-assimilating enzymes did not change [71], indicating that supraphysiological concentrations of ammonia may not interfere with the growth of breast cancer cells; however, they may stimulate breast cancer proliferation and growth and conversion to biomass [7]. Conversely, a study on colon cancer showed that accumulation of ammonia to a concentration of 10 mM downregulates the biosynthesis of polyamine and reduces the proliferation of cancer cells. P53, which is considered the most frequently mutated gene in human tumors, represses the urea cycle to suppress ureagenesis and the elimination of ammonia, thereby inhibiting tumor growth [8]. The difference between the two findings may be owing to the differences in the concentration of ammonia. An appropriate concentration of ammonia can therefore promote the proliferation of cancer cells.

However, it is difficult to replace GLN with ammonia as the only nitrogen source for cancer cell metabolism. Studies by Moreno-Sánchez et al. on a variety of cancers, such as ovarian, colon, breast, and prostate cancers, revealed that a moderate concentration of ammonia (0.1–10 mM) increases the proliferation of cancer cells. However, when GLN was removed from the medium, the growth rate of HeLa and MDA-MB-231 cell lines sharply declined [73]. The addition of NH4Cl (1–10 mM) could not rescue these two cell phenotypes. This shows that GLN remains an indispensable nutrient for cancer progression with a strong metastatic ability. Unlike tumor cells, fibroblasts are more sensitive to changes in ammonia concentration. When the concentration of ammonia was increased to 1 mM in the medium, it became too toxic for both mouse and human fibroblasts [73, 74].

The ability of ammonia assimilation in tumor cell lines with stronger metastatic ability was higher than that in non-metastatic tumors. GDH mRNA and protein expression in metastatic tumors was higher than that in non-metastatic tumors [75, 76]. Research on breast cancer indicated that GDH downregulation suppressed ammonia utilization and addition of carbamoyl phosphate synthetase I and GLN synthetase does not rescue this effect. In addition, cancer cells express more GLS1 (kidney-type glutaminase) and GDH than stromal cells [77, 78]. In another study, ammonia significantly increased the expression of GDH and GLS in metastatic hepatocellular carcinoma Hep3B cancer cells [54]. Thus, the utilization of ammonia in cancer cells is closely related to GDH.

Researchers have shown that an H+ channel-like membrane transporter (SLC4A11), which is sensitive to ammonia, is expressed in both cancer cells and fibroblasts. SLC4A11 is located in the inner mitochondrial membrane of fibroblasts and is sensitive to ammonia. This sensitivity enables the enhancement of electron transport chain activity, GLN-dependent oxygen consumption, and regulation of ATP levels by reducing ROS production. In GLN-addicted colon cancer cells, SLC4A11 knockdown downregulated GLN catabolism, ROS production, and cell proliferation [79]. Therefore, ammonia acts as a regulator of mitochondrial oxidative stress and promotes GLN catabolism.

Function of GLN and ammonia in tumor cell nucleotide synthesis

GLN is a material supplier for N-3 and N-9 of adenine and guanine, which is limited by PRPP amidotransferase, which transfers the amino group to the N-glycosidic bond in purine nucleotides [80].

There are two main methods for the de novo synthesis of pyrimidine. The most common way is to synthesize carbamoyl phosphate with GLN as a raw reagent under catalysis by carbamoyl phosphate synthetase II (CPS2). Aspartate transcarbamylase transfers the carbamoyl group to the amino group of aspartic acid to form carbamoyl aspartate. Carbamyl aspartic acid is dehydrated and cyclized to produce dihydroorotic acid, which is then dehydrogenated to form orotic acid (pyrimidine derivative). Orotic acid interacts with PRPP to produce orotic acid nucleotides, which are decarboxylated to form uridine acid [81].

Using inorganic ammonia as a raw material is another way to produce pyrimidine. CPS1 in the mitochondria is used to catalyze the synthesis of carbamoyl phosphate. In previous research, CPS1 was found to be the initiating enzyme of the urea cycle, which plays a role in the conversion of ammonia ions to the less toxic urea, enabling its excretion through the kidneys [7, 82]. Kim et al. demonstrated that carbamoyl phosphate catalyzed by CPS1 can be used to synthesize pyrimidine. The suppression of CPS1 in lung cancer cells leads to pyrimidine synthesis disorder and inhibits tumor growth and proliferation. Addition of exogenous pyrimidine can reverse this DNA damage and rescue growth; however, the process of inhibiting tumor growth is unrelated to the accumulation of ammonia [82].

Bidirectional crosstalk between cancer associated fibroblasts and cancer cells in GLN and ammonia metabolic pathways

GLN not only plays an important role in tumor cells but is also a very important component of the TME as a whole. In addition to the uptake and secretion of GLN, the excretion and utilization of ammonia are closely related to various components of the TME, especially CAFs. Here, we review the roles of GLN in the transport between cancer cells and CAFs and the metabolic regulation of GLN as a signaling molecule between cells.

Transport and metabolism of GLN and ammonia in cancer cells and CAFs

As mentioned earlier, cells depend on exogenous GLN as an N donor. Ammonia, which is metabolized using GLN, also plays an important role in regulating the metabolism of tumor cells and CAFs in the TME.

CAFs are stimulated by the ammonia in the TME that is secreted by cancer cells, triggering the activation of autophagy-related signals. In addition, the ammonia taken up by the CAFs in the TME can reduce mitochondrial viability. Together, these two processes cause CAFs to secrete high levels of GLN into the TME. Subsequently, GLN is taken up by cancer cells and metabolized to α-Ketoglutaric acid (α-KG) via the TCA cycle to ultimately increase mitochondrial activity [9]. Simultaneously, GLN stimulates TIGAR activation and inhibits autophagy in cancer cells. The transportation processes of GLN are different in different cancers. For example, pancreatic ductal adenocarcinoma (PDAC) is a cancer with rich stromal cells and poor blood vessel formation and does not have sufficient GLN supply through the serum [83]. However, PDAC cells use micropinocytosis to swallow extracellular proteins and utilize GLN and other amino acids using lysosomes [83,84,85]. Another route for cancer cell uptake of GLN from the TME is via extracellular vesicles that are released from neighboring cells. A study by Zhao et al. showed that CAFs-derived exosomes provided exosomal cargo and disrupted mitochondrial oxidative metabolism. CAFs-derived exosomes increase GLN reductive carboxylation for biosynthesis in prostate cancer cells by inhibiting the electron transport chain [56]. At the same time, tumor cells, especially epithelial cancer cells, utilize GLN and convert it to both ammonia and glutamate. Among these, ammonia leads to positive feedback and thus promotes CAFs autophagy and support the entry of GLN and other compounds as raw materials in the metabolic pathway [86]. However, compared with CAFs, cancer cells have a stronger resistance to autophagy induced by elevated ammonia levels [16, 86]. Autophagy in CAFs is more common than that in normal fibroblasts in lung cancer [87]. Moreover, some studies have shown that autophagy and senescence markers are highly expressed in stromal cells in breast and lung cancers. Higher matrix autophagy leads to more severe tumor phenotypes, such as the overexpression of Beclin-1 or the loss of Cav-1 in fibroblasts [47]. Similarly, other studies demonstrated that downregulation of Cav-1 in fibroblasts induced a four-fold increase in tumor size [87,88,89]. In addition, peroxisome proliferator-activated receptor γ (PPARγ) is an antidiabetic target that has a controversial role in cancer therapy. PPARγ is overexpressed in breast CAFs, which promotes autophagy and senescence by activating the HIF1-α and NF-κB pathways. This subsequently promotes the secretion of GLN and other metabolic materials into the TME to enhance the regulatory potential of cancer cells. However, overexpression of PPARγ in cancer cells also leads to modest inhibition of angiogenesis, which suppresses tumor growth [90].

Under some conditions, the release of GLN is not associated with autophagy. Analyses of gene and protein levels in ovarian cancer stroma have shown that expression levels of enzymes that catalyze the synthesis of intracellular GLN, such as glutamic-oxaloacetic transaminase ½ and branch chain amino acid transaminase 1, are higher in CAFs than in normal fibroblasts (NAFs). Half of the glutamate in CAFs, which is the raw material of GLN, is synthesized by the intracellular GLN metabolic pathway, and the other half is transferred from the TME by transporters. Subsequently, patient-derived CAFs secrete GLN into the TME at a rate of 25 pmol/K cells/h, whereas NAFs do not. Cancer cells can also promote GLN secretion using CAFs. CAFs synthesize GLN at the maximum rate when co-cultured with cancer cells [91]. However, on culturing cancer cells that lack GLN, CAFs synthesize more GLN using asparagine and aspartate as raw materials to restore the proliferation of cancer cells [73]. This GLN synthesis can be suppressed by exogenous GS. However, it cannot be suppressed by a GLS inhibitor or GLS siRNA, or even chloroquine, indicating that CAFs autophagy induced by cancer cells lead to CAFs providing nutrition to cancer cells. In conclusion, the transport of GLN and ammonia between CAFs and cancer cells in the TME can be affected by autophagy [92, 93].

Decomposition and utilization of GLN and ammonia by tumor fibroblasts are regulated by tumor cells

Breast cancer cells activate MYC in CAFs by secreting exosomal microRNA-105, which induces an increase in GLN and glucose metabolism, thus promoting the utilization of lactic acid and ammonia for detoxification and leading to the sustainable growth of tumors [94]. High MYC expression in cancer cells promotes microRNA-105 secretion, which in turn acts on CAFs to stimulate MYC activation, thus extending the effects of MYC originating from cancer cells. CAFs activated by microRNA-105 significantly increased the catabolism of both GLN and glucose while increasing the expression of GLS and SLC1A5 [94]. The levels of glutamate and lactate increased significantly, resulting in accelerated extracellular acidification. Two-dimensional NMR spectroscopy showed that labeled glutamate and acetate exhibited remarkably increased secretion by CAFs and could be involved in fueling cancer cells. Simultaneously inducing glycolysis and GLN decomposition in CAFs can enhance the metabolic flexibility of cancer cells, increase the use of alternative nutrients, and enhance the survival ability under single nutrient deprivation conditions. Simultaneously microRNA-105 could significantly increase the utilization of ammonia to synthesize GLN; thus, when nutrient levels are low and metabolic byproducts accumulate, these CAFs detoxify by converting metabolic waste products (including lactic acid and ammonia) into energy-rich metabolites [42, 91]. When nutrition is adequate, the CAFs, reprogrammed by microRNA-105, can enhance glucose and GLN metabolism to provide fuel for neighboring cancer cells. In addition, breast cancer cells showed higher metastasis and migration abilities when co-cultured with CAFs. Therefore, microRNA-105-mediated stromal cell metabolic reprogramming promotes the continuous growth of tumors by regulating the shared metabolic environment [94].

To better understand the transmission of GLN and ammonia between tumor cells and CAFs, a study established mathematical models on this metabolic transmission of GLN and ammonia. This research group found that it was better to achieve the effect of decomposing tumor cells and utilize GLN-enriched CAFs to consume part of the ammonia to form a metabolic circuit within 48 h [95]. However, this group only performed mathematical modeling for breast cancer cell lines and did not consider many other factors, such as surrounding endothelial cells and immune cells. In future studies, the mathematical model should be improved in relation to metabolism, thereby reducing the workload in actual experiments. It reduces the tenuous links of the experiment; any conclusions drawn from the model can then be verified with actual experiments. This may be an effective evaluation method in the field of metabolic studies.

Effects of GLN and ammonia on the movement and transformation of tumor cells and CAFs

GLN can be used as an inducer of tumor metastasis. CAFs perceive the GLN concentration in the environment and actively metastasize to high GLN regions while secreting proteases and cytokines to promote the migration of cancer cells behind CAFs as helpers. Roberts et al. found that cancer cells cultured in low GLN were far more tolerant than CAFs. GLN level at the center of breast cancer tumors was lower than in the peripheral area [96]. By simulating the GLN distribution gradient in breast cancer cells, CAFs were found to transfer from low-GLN areas to high-GLN areas, i.e., CAFs tended to migrate to the periphery of the tumor. When receiving the low GLN signature, CAFs activate TRAF, a ubiquitin ligase regulating AKT pathway [97]. TRAF regulates the polarized distribution of AKT2 with the concentration of GLN, which may then lead to the directional migration of CAFs. CAFs also drive cancer cell migration by stimulating the TGF-β-Snail1 axis, which is activated by cytokines derived from CAFs. Cancer cells do not migrate to the high GLN area when cultured alone; however, when co-cultured with CAFs, cancer cells begin to migrate, indicating that CAFs and GLN play a significant role in breast cancer metastasis [98].

In addition, GLS plays an important role in the phenotypic changes in the endothelial–mesenchymal transition (EMT) of tumor cells and CAFs. TGF-β is a crucial factor that promotes tumor proliferation and growth [99]. Silencing GLS during EMT, induced by TGF-β, can reverse this process. Moreover, GLS overexpression is a key factor for TGF-β-induced CAFs to develop a myofibroblast phenotype. Therefore, GLN metabolism is indispensable in TGF-β-promoting cancer [66, 100, 101].

Clinical application of GLN and ammonia

Detection of GLN and ammonia utilization for cancer diagnoses

Fluorodeoxyglucose-positron emission tomography scanning is an imaging technology based on the utilization of glucose, which shows the area utilizing more glucose compared to the surrounding areas, thus indicating the possible cancer focus [102]. However, some cancers cannot be detected by positron emission tomography. The survival of tumor cells inevitably requires a lot of energy, and these cells will have found other ways for energy supply. GLN is a potential alternative fuel, but tumor imaging agents based on GLN are still being developed [103].

Therapeutic strategies utilizing GLN and ammonia regulation

Consistent with the varied effects of GLN in different tumors, it can have distinct effects in different areas of the human body. Current GLN treatments mainly cover the following aspects: reduction in the plasma GLN concentration, inhibition of GLN uptake by tumor cells, use of GLN analogs to decrease tumor cell metabolism, and inhibition of key GLN metabolism enzymes in tumor cells. l-Asparaginase, an essential chemotherapy component in pediatric acute lymphoblastic leukemia, acts by breaking down GLN; however, in the treatment of adult pancreatic carcinoma, l-asparaginase shows unavoidably serious toxicity [24, 104]. Phenylacetate and benzoate have been approved by the FDA for use in the treatment of patients with congenital urea cycle disorders [105]. The combination injection of sodium phenylacetate and sodium benzoate showed remarkable lowering of plasma ammonium levels, but no advances have been made for its application in cancer therapy [105]. This may be because lowering blood GLN levels may cause serious gastrointestinal side effects [106].

Suppression of GLN uptake in cancer cells

One major component that supports cancer cells in the uptake of GLN is SLC1A5. Therefore, downregulation of SCL1A5 can reduce growth and proliferation of cells [28]. SLC1A5 is highly expressed in many types of cancers, such as breast, pancreatic, and colon cancers [107,108,109]. L-g-glutamyl-p-nitroanilide is an inhibitor of SLC1A5 that leads to GLN starvation in cells and inhibits GLN-dependent mTOR activation, thus suppressing cancer progression [9, 63, 110,111,112]. Moreover, deletion of SLC1A5 and SLC7A11 in mice does not lead to any obvious phenotypes or death [113, 114]. Therefore, both SLC1A5 and SLC7A11 are potential drug targets for cancer therapy. A few ongoing clinical trials are experimentally targeting the SLC7A11 receptor(NCT03965689) with sulfasalazine, a common drug in the treatment of rheumatic and inflammatory bowel diseases; this therapy has been reported to reduce cell proliferation in mice and several cell lines [115].

Administration of GLN analogs is another way to target the GLN pathway, such as the incorporation of antimetabolites in both DNA and RNA. GLN analogs interfere with the synthesis of both purines and pyrimidines. The GLN analog 6-diazo-5-oxo-L-norleucine (L-DON) showed promising preclinical data on its efficacy as an antimetabolite and as a GLS inhibitor; however, it was unsuitable for clinical use because of its excessive toxicity (neurotoxicity, myelosuppression, nausea, and vomiting) [116]. To enhance the effect of L-DON and reduce toxicity, it was co-administrated with PEGylated GLS. As expected, GLN depletion by the action of GLS resulted in a lower distribution of L-DON, leading to an improved toxicity profile. Despite this progress, this therapeutic approach needs further evaluation [117]. Because of the similarity of GLN metabolism between normal cells and cancer cells, GLN therapy often has unacceptable side effects. Thus, further research on therapeutic options targeting GLN metabolism will have two main strategies: on the one hand identifying the differences in glutamine metabolism between tumor cells and on the other hand, increasing the efficacy and reducing the side effects by dual targeting of cancer cells and CAFs, based on the characteristics of the TME.

Many recent clinical trials have focused on GLS and GDH inhibitors, such as compound 968, CB839, and BPTES. However, fatal side effects have been the major limitation in GLN catabolism therapy. Moreover, compound 968 and BPTES showed inhibitory potential in cell cultures [118]. Although the selective GLS inhibitor, CB839, is under clinical investigation, most compounds stagnated in clinical trial phases 1 and 2 (Table 1). CAFs play important roles in the metabolism of GLN and ammonia [7]. Additionally, animal experiments have shown that a combination therapy targeting GLS in cancer cells and GLUL in CAFs is better than using only a single target. This indicates that a combination therapy targeting CAFs along with an inhibitory drug may be a novel strategy for tumor treatment [91].

Table 1 Clinical research of targeting GLS [127]

Blocking ammonia reuse

CPS1 has been a target of several clinical investigations in patients with adrenal disease. Till date, there are no known reports on its application in cancer therapy. Celiktas et al. found that a combination of chemotherapy agents and CPS1 knockdown in vitro greatly reduced cell viability in lung adenocarcinoma [119], suggesting that CPS1 is a new target for cancer therapy and thus emphasizing the need for CPS1 inhibitors. Yao et al. developed a high-throughput screening enzyme assay for CPS1 inhibitor candidates and identified H3B-120 as a promising compound. They further evaluated determined the mechanism by which H3B-120 competes with ATP during synthesizing carbamoyl phosphate synthesis. H3B-120 almost completely inhibited the activity of CPS1 but had no effect on CPS2, aspartyl transcarbamylase, and dihydroorotase, which catalyze the first three steps in the de novo pyrimidine synthetic pathway [120]. Therefore, we believe that further studies on CPS1 inhibitors are warranted.

Cancer-associated drug resistance via GLN metabolism

Tumor drug resistance is a major challenge in any tumor treatment. Studies have shown that increased drug resistance is generally associated with CAFs [121], partly because of the regulation of GLN metabolism by CAFs, leading to drug resistance [86]. In the treatment of prostate cancer, androgen deprivation therapy (ADT)-induced GLN secretion by CAFs is a major cause of ADT resistance. The uptake of GLN by epithelial cells had a similar effect to that of a positive feedback mechanism. L-GLN increased the expression of SLC1A5 and SCL38A2 in a time-dependent manner, and SLC38A4 was also expressed in a GLN-dependent manner. GLN uptake promoted both GLS and GLS2 mRNA expression after 6 h of stimulation, which promoted the use of GLN by tumor cells while stimulating downstream mTOR signaling to promote tumor progression. In addition, GLN secreted by CAFs induce tumor proliferation and differentiation into a more invasive PCA phenotype, namely PCA neuroendocrine differentiation. GLN secretion is sufficient and necessary for this to occur. Studies have shown that in human prostate cancer tissue, RASAL3 methylation levels in CAFs were much higher than those in NAFs. Ras activated macropinocytosis in CAFs and subsequently increased their GLN secretion. Finally, CAFs significantly increased the levels of aminoamide and glutamic acid in cancer cells. A few Krebs cycle intermediates, such as succinate, fumarate, and malate, were significantly elevated and increased the energy metabolism in cancer cells. The significant increase in the level of GLN-derived aspartic acid in epithelial cells co-cultured with CAFs indicates the abundance of a key oxidized precursor of purines and pyrimidines, which further supports cancer cell proliferation [122]. ADT acts by precisely promoting the increase in GLN secretion caused by the apparent silencing of RASAL3, thus increasing drug resistance [123]. Therefore, prostate cancer treatment that involves controlling the CAF-mediated increase in TME GLN level is a promising tumor intervention method.

Radiotherapy is a routine method of tumor treatment, but studies have found that radiation can induce CAFs and promote the utilization of GLNs [124, 125]. Moreover, the basic properties of α-SMA and collagen did not change significantly after irradiation. However, it caused DNA double-strand breaks, p53 accumulation, and cell cycle arrest in CAFs. IGF1, a paracrine factor released by radiotherapy-treated CAFs, induces IGF1R/InsR phosphorylation in cancer cells, leading to Akt activation. The activated Akt pathway then stimulates mTOR and p70S6 kinase to participate in protein synthesis and cell growth, inducing the promotion of cancer cell survival. IGF1R signaling stimulates an early increase in glucose uptake and lactate release, followed by a decrease in extracellular GLN; moreover, GLN metabolism and transport genes reduce transcription, which accelerates GLN absorption and utilization, resists the damage caused by radiation, and stimulates cancer cell proliferation and metastasis of. Therefore, some patients who are not sensitive to radiotherapy may be protected by CAFs, which, in turn, promote the utilization of GLN in tumor cells to resist injury [126].

Conclusion

GLN and ammonia play important roles in both biosynthesis and signal transduction. Accumulating evidence has shown that GLN and ammonia levels are also regulated by CAFs. CAFs not only provide nutrients and stimulation for cancer cells but also provide essential physical support that collectively adapts to the metabolic needs of cancer cells; thus, they participate in tumorigenesis. Hence, the metabolic interplay between CAFs and cancer cells is considered an area of vulnerability for GLS therapy. Therefore, targeting the GLN pathway in cancer is not a new idea for cancer therapy, but dual targeting of cancer cells and CAFs is a more promising way to treat cancer.

Thus, CAFs represent a new opportunity for the study of ammonia metabolism in tumor cells. CAFs, being the largest group of cells in the TME, show a remarkable difference in ammonia sensitivity compared to tumor cells, thus implying that the regulation of inorganic ammonia metabolism in tumors is closely related to CAFs. Although research on ammonia metabolism is increasing, we are only at the tip of the iceberg.

Availability of data and materials

The datasets used or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

ADT:

Androgen deprivation therapy

ALL:

Acute lymphocytic leukemia

AML:

Acute myeloid leukemia

Arg:

Ariginine

α-KG:

α-Ketoglutaric acid

CAFs:

Cancer-associated fibroblasts

Cit:

Citrate

CPS1:

Carbamoyl phosphate synthetase I

CPS2:

Carbamoyl phosphate synthetase II

CRC:

Colorectal carcinoma

EAAs:

Essential amino acids

GLN:

Glutamine

GS:

Glutamine synthetase

TME:

Tumor microenvironment

ECM:

Extracellular matrix

EMT:

Endothelial–mesenchymal transition

GDH:

Glutamate dehydrogenase

Glc:

Glucose

GLS:

Glutaminase

GLS2:

Liver-type glutaminase

GLS1:

Kidney-type glutaminase

Glu:

Glutamate

GLUL:

Glutamate ammonia ligase

GSH:

Glutathione

Lac:

Lactose

L-DON:

6-Diazo-5-oxo-l-norleucine

MAPK:

Mitogen-activated protein kinase

mTOR:

Mammalian target of rapamycin

mTORC1:

MTOR complex 1

NAFs:

Normal fibroblasts

NSCLC:

Non-small cell lung cancer

Orn:

Ornithine

PDAC:

Pancreatic ductal adenocarcinoma

PPARγ:

Peroxisome proliferator-activated receptor γ

PRPP:

Phosphoribosylpyrophosphate

PYR:

Pyruvate.

RAG:

Ras-related GTPase

ROS:

Reactive oxygen species

TNBC:

Triple negative breast cancer

References

  1. 1.

    DeBerardinis RJ, Cheng T. Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29(3):313–24.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  2. 2.

    Bode BP, Fuchs BC, Hurley BP, Conroy JL, Suetterlin JE, Tanabe KK, Rhoads DB, Abcouwer SF, Souba WW. Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am J Physiol Gastrointest Liver Physiol. 2002;283(5):G1062-1073.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  3. 3.

    Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(10):619–34.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Tardito S, Oudin A, Ahmed SU, Fack F, Keunen O, Zheng L, Miletic H, Sakariassen P, Weinstock A, Wagner A, et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol. 2015;17(12):1556–68.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Conrad M, Schothorst J, Kankipati HN, Van Zeebroeck G, Rubio-Texeira M, Thevelein JM. Nutrient sensing and signaling in the yeast Saccharomyces cerevisiae. FEMS Microbiol Rev. 2014;38(2):254–99.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  6. 6.

    Li T, Le A. Glutamine metabolism in cancer. Adv Exp Med Biol. 2018;1063:13–32.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  7. 7.

    Spinelli JB, Yoon H, Ringel AE, Jeanfavre S, Clish CB, Haigis MC. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. Science. 2017;358(6365):941–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Li L, Mao Y, Zhao L, Li L, Wu J, Zhao M, Du W, Yu L, Jiang P. p53 regulation of ammonia metabolism through urea cycle controls polyamine biosynthesis. Nature. 2019;567(7747):253–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  9. 9.

    Yang L, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017;19:163–94.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  10. 10.

    Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem. 2007;101(4):805–15.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119–50.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Kadel D, Zhang Y, Sun HR, Zhao Y, Dong QZ, Qin LX. Current perspectives of cancer-associated fibroblast in therapeutic resistance: potential mechanism and future strategy. Cell Biol Toxicol. 2019;35(5):407–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Zeltz C, Primac I, Erusappan P, Alam J, Noel A, Gullberg D. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins. Semin Cancer Biol. 2020;62:166–81.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer. 2017;3(3):169–80.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Eng CH, Yu K, Lucas J, White E, Abraham RT. Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci Signal. 2010;3(119):ra31.

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Arneth B. Tumor microenvironment. Medicina (Kaunas). 2019;56:1.

    Article  Google Scholar 

  18. 18.

    Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3):297–308.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Eagle H. Nutrition needs of mammalian cells in tissue culture. Science. 1955;122(3168):501–14.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336(6084):1040–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Hosios AM, Hecht VC, Danai LV, Johnson MO, Rathmell JC, Steinhauser ML, Manalis SR, Vander Heiden MG. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev Cell. 2016;36(5):540–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Davidson SM, Papagiannakopoulos T, Olenchock BA, Heyman JE, Keibler MA, Luengo A, Bauer MR, Jha AK, O’Brien JP, Pierce KA, et al. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 2016;23(3):517–28.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Toda K, Nishikawa G, Iwamoto M, Itatani Y, Takahashi R, Sakai Y, Kawada K. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer. Int J Mol Sci. 2017;18:8.

    Article  CAS  Google Scholar 

  25. 25.

    Vanhove K, Derveaux E, Graulus G, Mesotten L, Thomeer M, Noben J, Guedens W, Adriaensens P. Glutamine addiction and therapeutic strategies in lung cancer. Int J Mol Sci. 2019;20:2.

    Article  CAS  Google Scholar 

  26. 26.

    Sniegowski T, Korac K, Bhutia YD, Ganapathy V. SLC6A14 and SLC38A5 drive the glutaminolysis and serine-glycine-one-carbon pathways in cancer. Pharmaceuticals (Basel). 2021;14:3.

    Article  CAS  Google Scholar 

  27. 27.

    Liu Y, Zhao T, Li Z, Wang L, Yuan S, Sun L. The role of ASCT2 in cancer: a review. Eur J Pharmacol. 2018;837:81–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  28. 28.

    Hassanein M, Hoeksema MD, Shiota M, Qian J, Harris BK, Chen H, Clark JE, Alborn WE, Eisenberg R, Massion PP. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin Cancer Res. 2013;19(3):560–70.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  29. 29.

    Liu P, Ge M, Hu J, Li X, Che L, Sun K, Cheng L, Huang Y, Pilo MG, Cigliano A, et al. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Hepatology. 2017;66(1):167–81.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  30. 30.

    Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F, Ruller C, Lau E, Kim H, Brill LM, et al. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell. 2015;27(3):354–69.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Dong J, Xiao D, Zhao Z, Ren P, Li C, Hu Y, Shi J, Su H, Wang L, Liu H, et al. Epigenetic silencing of microRNA-137 enhances ASCT2 expression and tumor glutamine metabolism. Oncogenesis. 2017;6(7):356.

    Article  CAS  Google Scholar 

  32. 32.

    Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, et al. LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res. 2011;3(5):468–78.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Pocasap P, Weerapreeyakul N, Timonen J, Järvinen J, Leppänen J, Kärkkäinen J, Rautio J. Tyrosine-chlorambucil conjugates facilitate cellular uptake through L-type amino acid transporter 1 (LAT1) in human breast cancer cell line MCF-7. Int J Mol Sci. 2020;21:6.

    Article  CAS  Google Scholar 

  34. 34.

    Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Aboody KS. SLC7A11 overexpression in glioblastoma is associated with increased cancer stem cell-like properties. Stem Cells Dev. 2017;26(17):1236–46.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. 35.

    Lin W, Wang C, Liu G, Bi C, Wang X, Zhou Q, Jin H. SLC7A11/xCT in cancer: biological functions and therapeutic implications. Am J Cancer Res. 2020;10(10):3106–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Lim JKM, Delaidelli A, Minaker SW, Zhang HF, Colovic M, Yang H, Negri GL, von Karstedt S, Lockwood WW, Schaffer P, et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci USA. 2019;116(19):9433–42.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Li C, Chen H, Lan Z, He S, Chen R, Wang F, Liu Z, Li K, Cheng L, Liu Y, et al. mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis. Cell Death Differ. 2019;26(10):2015–28.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Song X, Zhu S, Chen P, Hou W, Wen Q, Liu J, Xie Y, Liu J, Klionsky DJ, Kroemer G, et al. AMPK-mediated BECN1 phosphorylation promotes ferroptosis by directly blocking system X(c)(-) activity. Curr Biol. 2018;28(15):2388-2399.e2385.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Wang L, Liu Y, Du T, Yang H, Lei L, Guo M, Ding HF, Zhang J, Wang H, Chen X, et al. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc(). Cell Death Differ. 2020;27(2):662–75.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  40. 40.

    Linher-Melville K, Haftchenary S, Gunning P, Singh G. Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells. Mol Cell Biochem. 2015;405(1–2):205–21.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  41. 41.

    Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Bott AJ, Peng IC, Fan Y, Faubert B, Zhao L, Li J, Neidler S, Sun Y, Jaber N, Krokowski D, et al. Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metab. 2015;22(6):1068–77.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Wang T, Cai B, Ding M, Su Z, Liu Y, Shen L. c-Myc overexpression promotes oral cancer cell proliferation and migration by enhancing glutaminase and glutamine synthetase activity. Am J Med Sci. 2019;358(3):235–42.

    PubMed  Article  PubMed Central  Google Scholar 

  44. 44.

    Chiodi I, Perini C, Berardi D, Mondello C. Asparagine sustains cellular proliferation and c-Myc expression in glutamine-starved cancer cells. Oncol Rep. 2021;45:6.

    Article  CAS  Google Scholar 

  45. 45.

    Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA. 2008;105(48):18782–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, Matés JM, Alonso FJ, Wang C, Seo Y, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012;15(2):157–70.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, Sedivy J, Cole M. c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev. 1998;12(24):3797–802.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–76.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Taylor PM. Amino acid transporters: éminences grises of nutrient signalling mechanisms? Biochem Soc Trans. 2009;37(Pt 1):237–41.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  51. 51.

    Schoonjans CA, Joudiou N, Brusa D, Corbet C, Feron O, Gallez B. Acidosis-induced metabolic reprogramming in tumor cells enhances the anti-proliferative activity of the PDK inhibitor dichloroacetate. Cancer Lett. 2020;470:18–28.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  52. 52.

    Zhu M, Wang XQ. Regulation of mTORC1 by small GTPases in response to nutrients. J Nutr. 2020;150(5):1004–11.

    PubMed  Article  PubMed Central  Google Scholar 

  53. 53.

    Meng D, Yang Q, Wang H, Melick CH, Navlani R, Frank AR, Jewell JL. Glutamine and asparagine activate mTORC1 independently of Rag GTPases. J Biol Chem. 2020;295(10):2890–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Drews L, Zimmermann M, Westhoff P, Brilhaus D, Poss RE, Bergmann L, Wiek C, Brenneisen P, Piekorz RP, Mettler-Altmann T, et al. Ammonia inhibits energy metabolism in astrocytes in a rapid and glutamate dehydrogenase 2-dependent manner. Dis Model Mech. 2020;13:10.

    Google Scholar 

  55. 55.

    Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA. 2010;107(16):7461–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, Marini JC, Tudawe T, Seviour EG, San Lucas FA, et al. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. Elife. 2016;5:e10250.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  57. 57.

    Shang M, Cappellesso F, Amorim R, Serneels J, Virga F, Eelen G, Carobbio S, Rincon MY, Maechler P, De Bock K, et al. Macrophage-derived glutamine boosts satellite cells and muscle regeneration. Nature. 2020;587(7835):626–31.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Matés JM, Campos-Sandoval JA, de Los S-J, Segura JA, Alonso FJ, Márquez J. Metabolic reprogramming of cancer by chemicals that target glutaminase isoenzymes. Curr Med Chem. 2020;27(32):5317–39.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  59. 59.

    Matés JM, Di Paola FJ, Campos-Sandoval JA, Mazurek S, Márquez J. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin Cell Dev Biol. 2020;98:34–43.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  60. 60.

    Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA. 2010;107(16):7455–60.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Saha SK, Islam SMR, Abdullah-Al-Wadud M, Islam S, Ali F, Park KS. Multiomics analysis reveals that GLS and GLS2 differentially modulate the clinical outcomes of cancer. J Clin Med. 2019;8:3.

    Google Scholar 

  62. 62.

    Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015; 348(6235):648–60.

  63. 63.

    Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521–34.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. 64.

    Kim DS, Jue SS, Lee SY, Kim YS, Shin SY, Kim EC. Effects of glutamine on proliferation, migration, and differentiation of human dental pulp cells. J Endod. 2014;40(8):1087–94.

    PubMed  Article  PubMed Central  Google Scholar 

  65. 65.

    Través PG, de Atauri P, Marín S, Pimentel-Santillana M, Rodríguez-Prados JC. Marín de Mas I, Selivanov VA, Martín-Sanz P, Boscá L, Cascante M: Relevance of the MEK/ERK signaling pathway in the metabolism of activated macrophages: a metabolomic approach. J Immunol. 2012;188(3):1402–10.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  66. 66.

    Vanhove K, Derveaux E, Graulus GJ, Mesotten L, Thomeer M, Noben JP, Guedens W, Adriaensens P. Glutamine addiction and therapeutic strategies in lung cancer. Int J Mol Sci. 2019;20:2.

    Article  CAS  Google Scholar 

  67. 67.

    Yuan L, Sheng X, Willson AK, Roque DR, Stine JE, Guo H, Jones HM, Zhou C, Bae-Jump VL. Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway. Endocr Relat Cancer. 2015;22(4):577–91.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  68. 68.

    Andreescu N, Puiu M, Niculescu M. Effects of dietary nutrients on epigenetic changes in cancer. Methods Mol Biol. 2018;1856:121–39.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  69. 69.

    Kappler M, Pabst U, Rot S, Taubert H, Wichmann H, Schubert J, Bache M, Weinholdt C, Immel UD, Grosse I, et al. Normoxic accumulation of HIF1α is associated with glutaminolysis. Clin Oral Investig. 2017;21(1):211–24.

    PubMed  Article  PubMed Central  Google Scholar 

  70. 70.

    Tapper EB, Jiang ZG, Patwardhan VR. Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. Mayo Clin Proc. 2015;90(5):646–58.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  71. 71.

    Dasarathy S, Mookerjee RP, Rackayova V, Rangroo Thrane V, Vairappan B, Ott P, Rose CF. Ammonia toxicity: from head to toe? Metab Brain Dis. 2017;32(2):529–38.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  72. 72.

    Meng M, Chen S, Lao T, Liang D, Sang N. Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. Cell Cycle. 2010;9(19):3921–32.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  73. 73.

    Moreno-Sánchez R, Marín-Hernández Á, Gallardo-Pérez JC, Pacheco-Velázquez SC, Robledo-Cadena DX, Padilla-Flores JA, Saavedra E, Rodríguez-Enríquez S. Physiological role of glutamate dehydrogenase in cancer cells. Front Oncol. 2020;10:429.

    PubMed  PubMed Central  Article  Google Scholar 

  74. 74.

    Lu Y, Wang L, Ding W, Wang D, Wang X, Luo Q, Zhu L. Ammonia mediates mitochondrial uncoupling and promotes glycolysis via HIF-1 activation in human breast cancer MDA-MB-231 cells. Biochem Biophys Res Commun. 2019;519(1):153–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  75. 75.

    Jin L, Li D, Alesi GN, Fan J, Kang HB, Lu Z, Boggon TJ, Jin P, Yi H, Wright ER, et al. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell. 2015;27(2):257–70.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. 76.

    Craze ML, El-Ansari R, Aleskandarany MA, Cheng KW, Alfarsi L, Masisi B, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, et al. Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Res Treat. 2019;174(1):79–91.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  77. 77.

    Kim S, Kim DH, Jung WH, Koo JS. Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocr Relat Cancer. 2013;20(3):339–48.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  78. 78.

    Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol. 2014;25:47–60.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  79. 79.

    Ogando DG, Choi M, Shyam R, Li S, Bonanno JA. Ammonia sensitive SLC4A11 mitochondrial uncoupling reduces glutamine induced oxidative stress. Redox Biol. 2019;26:101260.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  80. 80.

    Cory JG, Cory AH. Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia. Vivo. 2006;20(5):587–9.

    CAS  Google Scholar 

  81. 81.

    Wang L. Mitochondrial purine and pyrimidine metabolism and beyond. Nucleosides Nucleotides Nucleic Acids. 2016;35(10–12):578–94.

    CAS  PubMed  Article  Google Scholar 

  82. 82.

    Kim J, Hu Z, Cai L, Li K, Choi E, Faubert B, Bezwada D, Rodriguez-Canales J, Villalobos P, Lin YF, et al. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature. 2017;546(7656):168–72.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 2015;75(3):544–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  84. 84.

    Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497(7451):633–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  85. 85.

    Davidson SM, Jonas O, Keibler MA, Hou HW, Luengo A, Mayers JR, Wyckoff J, Del Rosario AM, Whitman M, Chin CR, et al. Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. Nat Med. 2017;23(2):235–41.

    CAS  PubMed  Article  Google Scholar 

  86. 86.

    Ko YH, Lin Z, Flomenberg N, Pestell RG, Howell A, Sotgia F, Lisanti MP, Martinez-Outschoorn UE. Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. Cancer Biol Ther. 2011;12(12):1085–97.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  87. 87.

    Chaudhri VK, Salzler GG, Dick SA, Buckman MS, Sordella R, Karoly ED, Mohney R, Stiles BM, Elemento O, Altorki NK, et al. Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor. Mol Cancer Res. 2013;11(6):579–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  88. 88.

    Capparelli C, Guido C, Whitaker-Menezes D, Bonuccelli G, Balliet R, Pestell TG, Goldberg AF, Pestell RG, Howell A, Sneddon S, et al. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle. 2012;11(12):2285–302.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  89. 89.

    Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle. 2010;9(17):3515–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  90. 90.

    Avena P, Anselmo W, Whitaker-Menezes D, Wang C, Pestell RG, Lamb RS, Hulit J, Casaburi I, Andò S, Martinez-Outschoorn UE, et al. Compartment-specific activation of PPARγ governs breast cancer tumor growth, via metabolic reprogramming and symbiosis. Cell Cycle. 2013;12(9):1360–70.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  91. 91.

    Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, et al. Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab. 2016;24(5):685–700.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  92. 92.

    Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13(4):890–901.

    CAS  PubMed  Article  Google Scholar 

  93. 93.

    Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, Delahanty G, Alt J, Rais R, Rojas C, Gao P, et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem. 2012;55(23):10551–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  94. 94.

    Yan W, Wu X, Zhou W, Fong MY, Cao M, Liu J, Liu X, Chen CH, Fadare O, Pizzo DP, et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol. 2018;20(5):597–609.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    Hinow P, Pinter G, Yan W, Wang SE. Modeling the bidirectional glutamine/ammonium conversion between cancer cells and cancer-associated fibroblasts. PeerJ. 2021;9:e10648.

    PubMed  PubMed Central  Article  Google Scholar 

  96. 96.

    Roberts E, Frankel S. Free amino acids in normal and neoplastic tissues of mice as studied by paper chromatography. Cancer Res. 1949;9(11):645–8.

    CAS  PubMed  Google Scholar 

  97. 97.

    Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009;325(5944):1134–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  98. 98.

    Mestre-Farrera A, Bruch-Oms M, Peña R, Rodríguez-Morató J, Alba-Castellón L, Comerma L, Quintela-Fandino M, Duñach M, Baulida J, Pozo ÓJ, et al. Glutamine-directed migration of cancer-activated fibroblasts facilitates epithelial tumor invasion. Cancer Res. 2021;81(2):438–51.

    CAS  PubMed  Article  Google Scholar 

  99. 99.

    Shi J, Feng J, Xie J, Mei Z, Shi T, Wang S, Du Y, Yang G, Wu Y, Cheng X, et al. Targeted blockade of TGF-β and IL-6/JAK2/STAT3 pathways inhibits lung cancer growth promoted by bone marrow-derived myofibroblasts. Sci Rep. 2017;7(1):8660.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  100. 100.

    Abulaiti A, Shintani Y, Funaki S, Nakagiri T, Inoue M, Sawabata N, Minami M, Okumura M. Interaction between non-small-cell lung cancer cells and fibroblasts via enhancement of TGF-β signaling by IL-6. Lung Cancer. 2013;82(2):204–13.

    PubMed  Article  PubMed Central  Google Scholar 

  101. 101.

    Reid MA, Wang WI, Rosales KR, Welliver MX, Pan M, Kong M. The B55α subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Mol Cell. 2013;50(2):200–11.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  102. 102.

    Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, et al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009;27(16):2697–704.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  103. 103.

    Ploessl K, Wang L, Lieberman BP, Qu W, Kung HF. Comparative evaluation of 18F-labeled glutamic acid and glutamine as tumor metabolic imaging agents. J Nucl Med. 2012;53(10):1616–24.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  104. 104.

    Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005;44(4):367–93.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  105. 105.

    Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med. 2007;356(22):2282–92.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  106. 106.

    Baskerville A, Hambleton P, Benbough JE. Pathological features of glutaminase toxicity. Br J Exp Pathol. 1980;61(2):132–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. 107.

    Yoo HC, Park SJ, Nam M, Kang J, Kim K, Yeo JH, Kim JK, Heo Y, Lee HS, Lee MY, et al. A variant of SLC1A5 Is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells. Cell Metab. 2020;31(2):267-283.e212.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  108. 108.

    van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, Gao D, Ritchie W, Feng Y, Bailey CG, Deng N, et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2016;35(24):3201–8.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  109. 109.

    Ma H, Wu Z, Peng J, Li Y, Huang H, Liao Y, Zhou M, Sun L, Huang N, Shi M, et al. Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab. Int J Cancer. 2018;142(12):2578–88.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  110. 110.

    Hare SH, Harvey AJ. mTOR function and therapeutic targeting in breast cancer. Am J Cancer Res. 2017;7(3):383–404.

    CAS  PubMed  PubMed Central  Google Scholar 

  111. 111.

    Moloughney JG, Kim PK, Vega-Cotto NM, Wu CC, Zhang S, Adlam M, Lynch T, Chou PC, Rabinowitz JD, Werlen G, et al. mTORC2 responds to glutamine catabolite levels to modulate the hexosamine biosynthesis enzyme GFAT1. Mol Cell. 2016;63(5):811–26.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  112. 112.

    Liu B, Huang ZB, Chen X, See YX, Chen ZK, Yao HK. Mammalian TARGET OF RAPAMYCIN 2 (MTOR2) and C-MYC modulate glucosamine-6-phosphate synthesis in glioblastoma (GBM) cells through glutamine: fructose-6-phosphate aminotransferase 1 (GFAT1). Cell Mol Neurobiol. 2019;39(3):415–34.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  113. 113.

    Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K, Moriguchi T, et al. Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem. 2005;280(45):37423–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  114. 114.

    Nakaya M, Xiao Y, Zhou X, Chang JH, Chang M, Cheng X, Blonska M, Lin X, Sun SC. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity. 2014;40(5):692–705.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  115. 115.

    Ji X, Qian J, Rahman SMJ, Siska PJ, Zou Y, Harris BK, Hoeksema MD, Trenary IA, Heidi C, Eisenberg R, et al. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene. 2018;37(36):5007–19.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  116. 116.

    Ahluwalia GS, Grem JL, Hao Z, Cooney DA. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther. 1990;46(2):243–71.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  117. 117.

    Mueller C, Al-Batran S, Jaeger E, Schmidt B, Bausch M, Unger C, Sethuraman N. A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors. J Clin Oncol. 2008;26(15):2533–2533.

    Article  Google Scholar 

  118. 118.

    Katt WP, Cerione RA. Glutaminase regulation in cancer cells: a druggable chain of events. Drug Discov Today. 2014;19(4):450–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  119. 119.

    Çeliktas M, Tanaka I, Tripathi SC, Fahrmann JF, Aguilar-Bonavides C, Villalobos P, Delgado O, Dhillon D, Dennison JB, Ostrin EJ, et al. Role of CPS1 in cell growth, metabolism and prognosis in LKB1-inactivated lung adenocarcinoma. J Natl Cancer Inst. 2017;109(3):1–9.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  120. 120.

    Yao S, Nguyen TV, Rolfe A, Agrawal AA, Ke J, Peng S, Colombo F, Yu S, Bouchard P, Wu J, et al. Small molecule inhibition of CPS1 activity through an allosteric pocket. Cell Chem Biol. 2020;27(3):259-268.e255.

    CAS  PubMed  Article  Google Scholar 

  121. 121.

    Li XY, Hu SQ, Xiao L. The cancer-associated fibroblasts and drug resistance. Eur Rev Med Pharmacol Sci. 2015;19(11):2112–9.

    PubMed  Google Scholar 

  122. 122.

    Rabinovich S, Adler L, Yizhak K, Sarver A, Silberman A, Agron S, Stettner N, Sun Q, Brandis A, Helbling D, et al. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature. 2015;527(7578):379–83.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  123. 123.

    Mishra R, Haldar S, Placencio V, Madhav A, Rohena-Rivera K, Agarwal P, Duong F, Angara B, Tripathi M, Liu Z, et al. Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. J Clin Invest. 2018;128(10):4472–84.

    PubMed  PubMed Central  Article  Google Scholar 

  124. 124.

    Wang Z, Tang Y, Tan Y, Wei Q, Yu W. Cancer-associated fibroblasts in radiotherapy: challenges and new opportunities. Cell Commun Signal. 2019;17(1):47.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  125. 125.

    Ansems M, Span PN. The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts. Clin Transl Radiat Oncol. 2020;22:90–7.

    PubMed  PubMed Central  Article  Google Scholar 

  126. 126.

    Tommelein J, De Vlieghere E, Verset L, Melsens E, Leenders J, Descamps B, Debucquoy A, Vanhove C, Pauwels P, Gespach CP, et al. Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF1R activation. Cancer Res. 2018;78(3):659–70.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  127. 127.

    ClinicalTrials.gov. U.S. National Library of Medicine. https://clinicaltrials.gov/. Accessed 21 May 2021.

Download references

Acknowledgements

We would like to thank the Jilin University for supporting this manuscript.

Funding

This study was supported by grants from Graduate Innovation Fund of Jilin University (No. 101832020CX299).

Author information

Affiliations

Authors

Contributions

XL have drafted the article. HZ and XY have revised the manuscript. WS and QN have contributed to the acquisition and interpretation of data. XF has designed the work. All authors have contributed to manuscript revision. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Xuedong Fang.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, X., Zhu, H., Sun, W. et al. Role of glutamine and its metabolite ammonia in crosstalk of cancer-associated fibroblasts and cancer cells. Cancer Cell Int 21, 479 (2021). https://doi.org/10.1186/s12935-021-02121-5

Download citation

Keywords

  • Cancer-associated fibroblasts
  • Glutamine
  • Ammonia
  • Cancer cells
  • Tumor microenvironment